Results 171 to 180 of about 4,593,278 (410)

Analysis of pathological remission degree and influencing factors of radical surgery after neoadjuvant immunotherapy combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma [PDF]

Zhongguo aizheng zazhi
Background and purpose: Radical surgery after neoadjuvant immunotherapy combined with chemotherapy (nICT) in patients with locally advanced esophageal squamous cell carcinoma (LAESCC) has good efficacy and safety, and it can improve the patients ...
LIAO Ziyi, PENG Yang, ZENG Beilei, MA Yingying, ZENG Li, GAN Kelun, MA Daiyuan
doaj   +1 more source

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial

JAMA Oncology, 2018
Importance Patients with borderline-resectable pancreatic ductal adenocarcinoma have historically poor outcomes with surgery followed by adjuvant chemotherapy. Evaluation of a total neoadjuvant approach with highly active therapy is warranted.
Janet E. Murphy, J. Wo, D. Ryan, Wenqing Jiang, B. Yeap, L. Drapek, L. Blaszkowsky, E. Kwak, Jill N. Allen, Jeffrey W. Clark, J. Faris, A. Zhu, L. Goyal, K. Lillemoe, T. Delaney, C. F. Fernandez-Del Castillo, C. Ferrone, T. Hong   +17 more
semanticscholar   +1 more source

The Emergence of Neoadjuvant Therapy in Advanced Melanoma

Melanoma Management, 2019
The discovery of immunotherapy and targeted therapy has introduced new and effective treatment options for advanced melanoma, providing therapeutic options where none existed before. The natural extension of these novel therapies is to identify their role in the neoadjuvant setting.
James Sun, Dennis A Kirichenko, Jonathan S Zager, Zeynep Eroglu   +3 more
openaire   +3 more sources

Long‐Term Survival of Two Versus Three Courses of Preoperative Cisplatin and Fluorouracil Plus Docetaxel for Locally Advanced Esophageal Cancer: A Multicenter Randomized Phase II Trial

Annals of Gastroenterological Surgery, EarlyView.
This multi‐institutional, randomized, phase II trial aimed to investigate the long‐term survival outcomes of two versus three courses of DCF for locally advanced esophageal squamous cell carcinoma (ESCC). The 5‐year overall survival and progression‐free survival rates for the three and two course groups were 70.7% vs. 63.8% (hazard ratio (HR) = 0.91, p 
Takahito Sugase, Hiroshi Miyata, Takashi Kanemura, Norihiro Matsuura, Tomoki Makino, Makoto Yamasaki, Koji Tanaka, Kotaro Yamashita, Kota Momose, Osamu Shiraishi, Keijiro Sugimura, Masaaki Motoori, Kazumasa Fujitani, Atsushi Takeno, Motohiro Hirao, Yutaka Kimura, Taroh Satoh, Masahiko Yano, Yuichiro Doki, Takushi Yasuda   +19 more
wiley   +1 more source

Surgical Procedure of Lateral Lymph Node Dissection for Advanced Lower Rectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
Lateral lymph node dissection (LLND) is an effective surgical approach for lower rectal cancer. This paper outlines key points from the Japan Society of Gastroenterological Surgery consensus meeting, including standardized LLND techniques and procedural highlights.
Mamoru Uemura, Jun Watanabe, Akio Shiomi, Takashi Akiyoshi, George J. Chang, Yukihide Kanemitsu, Ichiro Takemasa, Yoshiharu Sakai, Masahiko Watanabe, Itaru Endo   +9 more
wiley   +1 more source

Essential Updates 2023/2024: Recent Advances of Multimodal Approach in Patients for Gastric Cancer

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Gastric cancer remains a major global health burden, especially in East Asia. Recent years have brought significant advances in multimodal management, including surgery, perioperative chemotherapy, immunotherapy, and supportive care. This review summarizes key updates from 2023 to 2024, focusing on surgical innovations, perioperative systemic ...
Katsutoshi Shoda, Yoshihiko Kawaguchi, Suguru Maruyama, Daisuke Ichikawa   +3 more
wiley   +1 more source

Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy

Chronic Diseases and Translational Medicine, 2016
Neoadjuvant therapy has become the standard of care for locally advanced mid-low rectal cancer. Pathological complete response (pCR) can be achieved in 12%–38% of patients. Patients with pCR have the most favorable long-term outcomes.
Jian Cui, Hui Fang, Lin Zhang, Yun-Long Wu, Hai-Zeng Zhang   +4 more
doaj  

BreastRegNet: A Deep Learning Framework for Registration of Breast Faxitron and Histopathology Images [PDF]

arXiv
A standard treatment protocol for breast cancer entails administering neoadjuvant therapy followed by surgical removal of the tumor and surrounding tissue. Pathologists typically rely on cabinet X-ray radiographs, known as Faxitron, to examine the excised breast tissue and diagnose the extent of residual disease.
arxiv  

Neoadjuvant therapy for ovarian cancer

Chinese Clinical Oncology, 2018
Ovarian cancer (OC) is a common oncological disease, which affects approximately 1.5% of women and holds the first position in the structure of gynecological cancer mortality.
openaire   +3 more sources

Risk Evaluation of the NCD Risk Calculator for Open Pancreaticoduodenectomy in Elderly Patients: A Validation Study

Annals of Gastroenterological Surgery, EarlyView.
This study investigated the utility of the Japanese NCD risk calculator for preoperative assessment in elderly patients undergoing pancreaticoduodenectomy (PD), using a validation study design. In the training cohort, two preoperative factors—the predicted incidence of postoperative ADL decline ≥ 44.8% and Clavien–Dindo grade IV or higher complications
Nana Kimura, Ayaka Itoh, Ayano Sakai, Katsuhisa Hirano, Kenta Yagi, Naoya Takeda, Kazuto Shibuya, Isaku Yoshioka, Kenta Murotani, Tsutomu Fujii   +9 more
wiley   +1 more source